Robert Bissonnette

Robert Bissonnette

Sherbrooke Est
Montreal, QC, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 239 publications

Placebo Response in Randomised Controlled Trials of Systemic Therapies for Cutaneous Lupus Erythematosus: A Systematic Review and Meta-Analysis.

Placebo Response in Randomised Controlled Trials of Systemic Therapies for Cutaneous Lupus Erythematosus: A Systematic Review and Meta-Analysis.

Journal: Pharmaceutical medicine

Published: July 28, 2026

Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials.

Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials.

Journal: Dermatology and therapy

Published: June 24, 2026

Characterizing the Burden of Hand Dermatitis in Canada: A Cross-Sectional Survey of Disease Impact.

Characterizing the Burden of Hand Dermatitis in Canada: A Cross-Sectional Survey of Disease Impact.

Journal: Journal of cutaneous medicine and surgery

Published: May 27, 2026

EP262, an MRGPRX2 Antagonist for the Treatment of Atopic Dermatitis: Results From the Phase 2 Randomized EASE Study.

EP262, an MRGPRX2 Antagonist for the Treatment of Atopic Dermatitis: Results From the Phase 2 Randomized EASE Study.

Journal: Dermatology and therapy

Published: May 12, 2026

International Eczema Council Definitions of Low Disease Activity and Remission in Atopic Dermatitis: A Consensus Statement.

International Eczema Council Definitions of Low Disease Activity and Remission in Atopic Dermatitis: A Consensus Statement.

Journal: JAMA dermatology

Published: April 15, 2026

Burden and Etiopathogenesis of Chronic Hand Eczema: A Complex Interplay of Genes, Environment, and Exposures.

Burden and Etiopathogenesis of Chronic Hand Eczema: A Complex Interplay of Genes, Environment, and Exposures.

Journal: Journal of cutaneous medicine and surgery

Published: March 17, 2026

Maintenance of response with icotrokinra, a targeted oral peptide, for the treatment of moderate-to-severe plaque psoriasis: Randomized treatment withdrawal in adults from the phase 3, ICONIC-LEAD study.

Maintenance of response with icotrokinra, a targeted oral peptide, for the treatment of moderate-to-severe plaque psoriasis: Randomized treatment withdrawal in adults from the phase 3, ICONIC-LEAD study.

Journal: Journal of the American Academy of Dermatology

Published: February 24, 2026

Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findings.

Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findings.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: February 13, 2026

Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials.

Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials.

Journal: The British journal of dermatology

Published: January 30, 2026

Efficacy of abrocitinib and dupilumab on chronic hand eczema in patients with moderate-to-severe atopic dermatitis: a prespecified exploratory analysis of the phase 3 JADE DARE study.

Efficacy of abrocitinib and dupilumab on chronic hand eczema in patients with moderate-to-severe atopic dermatitis: a prespecified exploratory analysis of the phase 3 JADE DARE study.

Journal: Journal of the American Academy of Dermatology

Published: January 28, 2026

The Gut Microbiome of Non-Atopic Chronic Hand Eczema (CHE) Subjects is Distinct and Enriched in Immuno-Modulatory Bacteria Species compared to Atopic-CHE and Healthy Subjects.

The Gut Microbiome of Non-Atopic Chronic Hand Eczema (CHE) Subjects is Distinct and Enriched in Immuno-Modulatory Bacteria Species compared to Atopic-CHE and Healthy Subjects.

Journal: The British journal of dermatology

Published: November 06, 2025

Gut microbiome of patients with nonatopic chronic hand eczema (CHE) is distinct and enriched in immunomodulatory bacteria species compared with patients with atopic CHE and healthy individuals.

Gut microbiome of patients with nonatopic chronic hand eczema (CHE) is distinct and enriched in immunomodulatory bacteria species compared with patients with atopic CHE and healthy individuals.

Journal: The British journal of dermatology

Published: November 06, 2025

Showing 1-12 of 239

Last Updated: 09/26/2026